{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:08:34Z","timestamp":1792166914893,"version":"4.4.0"},"reference-count":38,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"China Resources Double-Crane Pharmaceutical Co., Ltd.","award":["HX-311230432"],"award-info":[{"award-number":["HX-311230432"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Hypertension constitutes the primary health burden of cardiovascular diseases, and the global control of blood pressure (BP) remains insufficient. Single pill combinations (SPCs) are employed as a means to streamline the management of poor BP control due to non-adherence and treatment inertia. The compound reserpine and triamterene tablets constitute a quadruple SPC, comprising reserpine 0.1\u2009mg, dihydralazine 12.5\u2009mg, hydrochlorothiazide 12.5\u2009mg and triamterene 12.5\u2009mg. It is widely employed in primary medical institutions and has favourable efficacy, tolerability and cost-effectiveness.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods and analysis<\/jats:title>\n<jats:p>The COSPQ-BP trial is a 12-week prospective randomised controlled trial to enrol 1332 patients with primary mild-to-moderate hypertension. Participants who meet the inclusion criteria will be randomly assigned to a 1:1 ratio to an intervention group (compound reserpine and triamterene tablets) or a control group (valsartan\/hydrochlorothiazide). The primary outcome will be mean changes from baseline in 24-hour ambulatory systolic BP after intervention for 12 weeks. The secondary outcomes have been predetermined and will primarily encompass the following: (1) changes in other BP measures, as well as changes in blood lipids, blood glucose and uric acid at 12 weeks and (2) evaluation of the impact of starting antihypertensive therapy with compound reserpine and triamterene tablets or valsartan\/hydrochlorothiazide on the depressive and anxiety statess of patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Ethics and dissemination<\/jats:title>\n<jats:p>The study protocol (version number: V5.0, version date: 17 January 2023) has been approved by the ethics committee (Biomedical Ethics Committee of West China Hospital of Sichuan University, approval number: Review (51) in 2023). Written informed consent will be obtained from each participant by researchers. The findings of this study will be disseminated through conference presentations and peer-reviewed publications.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>This study was registered at the Chinese Clinical Trials Registry (ChiCTR2300067920). The COSPQ-BP trial is currently enrolling. The study period will be from 1 January 2024 to 31 December 2025.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/bmjopen-2024-092109","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T03:45:12Z","timestamp":1739159112000},"page":"e092109","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Chinese traditional quadruple single pill combination versus valsartan\/hydrochlorothiazide for the treatment of hypertension (COSPQ-BP): study protocol for randomised controlled study"],"prefix":"10.1136","volume":"15","author":[{"given":"Shanshan","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runyu","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1594-5473","authenticated-orcid":false,"given":"Xianghao","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4456-6706","authenticated-orcid":false,"given":"Si","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtao","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6652-4328","authenticated-orcid":false,"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2025070104270962000_15.2.e092109.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30752-2"},{"key":"2025070104270962000_15.2.e092109.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01330-1"},{"key":"2025070104270962000_15.2.e092109.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071952","article-title":"Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: findings from six rounds of a national survey","volume":"380","author":"Zhang","year":"2023","journal-title":"BMJ"},{"key":"2025070104270962000_15.2.e092109.4","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","author":"Rahimi","year":"2021","journal-title":"The Lancet"},{"key":"2025070104270962000_15.2.e092109.5","doi-asserted-by":"crossref","first-page":"e411","DOI":"10.1016\/S2468-2667(17)30141-X","article-title":"Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data","volume":"2","author":"Attaei","year":"2017","journal-title":"Lancet Public Health"},{"key":"2025070104270962000_15.2.e092109.6","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(19)31293-0","article-title":"Blood pressure control: a challenge to global health systems","volume":"394","author":"Chow","year":"2019","journal-title":"Lancet"},{"key":"2025070104270962000_15.2.e092109.7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026582","article-title":"Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta-Analysis Involving 27 Million Patients","volume":"11","author":"Lee","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025070104270962000_15.2.e092109.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht219"},{"key":"2025070104270962000_15.2.e092109.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2009.02084.x"},{"key":"2025070104270962000_15.2.e092109.10","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006056","article-title":"Antihypertensive Medication Adherence and Risk of Cardiovascular Disease Among Older Adults: A Population-Based Cohort Study","volume":"6","author":"Yang","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2025070104270962000_15.2.e092109.11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1161\/HYPERTENSIONAHA.115.06731","article-title":"Medication Adherence and the Risk of Cardiovascular Mortality and Hospitalization Among Patients With Newly Prescribed Antihypertensive Medications","volume":"67","author":"Kim","year":"2016","journal-title":"Hypertension"},{"key":"2025070104270962000_15.2.e092109.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2020.08.003"},{"key":"2025070104270962000_15.2.e092109.13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"2025070104270962000_15.2.e092109.14","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002783"},{"key":"2025070104270962000_15.2.e092109.15","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1161\/HYPERTENSIONAHA.120.15866","article-title":"Impact of Therapeutic Inertia on Long-Term Blood Pressure Control: A Monte Carlo Simulation Study","volume":"77","author":"Augustin","year":"2021","journal-title":"Hypertension"},{"key":"2025070104270962000_15.2.e092109.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32478-9"},{"key":"2025070104270962000_15.2.e092109.17","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000203"},{"key":"2025070104270962000_15.2.e092109.18","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.18192"},{"key":"2025070104270962000_15.2.e092109.19","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"2025070104270962000_15.2.e092109.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"2025070104270962000_15.2.e092109.21","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.phrs.2017.09.011","article-title":"Combination drug treatment in hypertension","volume":"125","author":"Tsioufis","year":"2017","journal-title":"Pharmacol Res"},{"key":"2025070104270962000_15.2.e092109.22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5603\/CJ.a2022.0031","article-title":"Use of single pill combinations in the treatment of arterial hypertension in Poland: The current practice and guidelines, the impact on reimbursement spending and patient co-payment","volume":"29","author":"Czech","year":"2022","journal-title":"Cardiol J"},{"key":"2025070104270962000_15.2.e092109.23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41371-023-00811-3","article-title":"Cost-effectiveness analysis of initial treatment with single-pill combination antihypertensive medications","volume":"37","author":"Bryan","year":"2023","journal-title":"J Hum Hypertens"},{"key":"2025070104270962000_15.2.e092109.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.318729"},{"key":"2025070104270962000_15.2.e092109.25","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","article-title":"Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial","volume":"398","author":"Chow","year":"2021","journal-title":"Lancet"},{"key":"2025070104270962000_15.2.e092109.26","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/s41440-024-01658-y","article-title":"Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial","volume":"47","author":"Huffman","year":"2024","journal-title":"Hypertens Res"},{"key":"2025070104270962000_15.2.e092109.27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2024.18080","article-title":"Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial","volume":"332","author":"Ojji","year":"2024","journal-title":"JAMA"},{"key":"2025070104270962000_15.2.e092109.28","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/S0140-6736(24)01744-6","article-title":"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial","volume":"404","author":"Rodgers","year":"2024","journal-title":"Lancet"},{"key":"2025070104270962000_15.2.e092109.29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/jamacardio.2022.0471","article-title":"Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical Trial","volume":"7","author":"Gnanenthiran","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2025070104270962000_15.2.e092109.30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jamacardio.2023.0720","article-title":"Efficacy and Safety of Low-Dose Triple and Quadruple Combination Pills vs Monotherapy, Usual Care, or Placebo for the Initial Management of Hypertension: A Systematic Review and Meta-analysis","volume":"8","author":"Wang","year":"2023","journal-title":"JAMA Cardiol"},{"key":"2025070104270962000_15.2.e092109.31","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.120.15781"},{"key":"2025070104270962000_15.2.e092109.32","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1161\/HYPERTENSIONAHA.122.20810","article-title":"Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study","volume":"80","author":"Schmieder","year":"2023","journal-title":"Hypertension"},{"key":"2025070104270962000_15.2.e092109.33","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/jch.14207","article-title":"A double-blind, placebo-controlled trial on the antihypertensive treatment effect of a quadruple single-pill combination","volume":"23","author":"Hu","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"2025070104270962000_15.2.e092109.34","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/BF03256917","article-title":"Long-term efficacy and tolerability of a fixed-dose combination of antihypertensive agents: an open-label surveillance study in China","volume":"31","author":"Wu","year":"2011","journal-title":"Clin Drug Investig"},{"key":"2025070104270962000_15.2.e092109.35","article-title":"EVALUATION ON CLINICAL APPLICATION OF LOW-DOSE TRADITIONAL QUADRUPLE ANTIHYPERTENSIVE COMPOUND PREPARATION IN CHINA","volume":"41","author":"Sun\/Ningling","year":"2023","journal-title":"J Hypertens"},{"key":"2025070104270962000_15.2.e092109.36","first-page":"1057","article-title":"The antihypertensive effect of compound reserpine and triamterene tablets on the regulation of intestinal flora in rat","volume":"31","author":"Jiang","year":"2022","journal-title":"Chinese Journal of New Drugs"},{"key":"2025070104270962000_15.2.e092109.37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2025070104270962000_15.2.e092109.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-039447","article-title":"Internet-based patient- primary care physician-cardiologist integrated management model of hypertension in China: study protocol for a multicentre randomised controlled trial","volume":"10","author":"Ye","year":"2020","journal-title":"BMJ Open"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-092109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T16:06:14Z","timestamp":1754496374000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-092109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,26]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2024-092109"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-092109","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}